UroGen Pharma Ltd. (NASDAQ:URGN) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 49.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 104,600 shares of the company’s stock after buying an additional 34,537 shares during the period. Wellington Management Group LLP owned 0.45% of UroGen Pharma worth $1,569,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in URGN. China Universal Asset Management Co. Ltd. grew its position in UroGen Pharma by 361.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock valued at $54,000 after acquiring an additional 2,801 shares during the period. Allspring Global Investments Holdings LLC increased its position in UroGen Pharma by 31.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock worth $74,000 after purchasing an additional 1,191 shares in the last quarter. SG Americas Securities LLC purchased a new position in UroGen Pharma in the fourth quarter valued at approximately $131,000. Federated Hermes Inc. acquired a new position in UroGen Pharma during the third quarter valued at approximately $184,000. Finally, Sierra Summit Advisors LLC acquired a new position in UroGen Pharma during the fourth quarter valued at approximately $218,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

Shares of URGN stock opened at $16.48 on Tuesday. The company’s fifty day moving average price is $14.35 and its two-hundred day moving average price is $15.25. The firm has a market capitalization of $386.46 million, a P/E ratio of -4.85 and a beta of 1.12. UroGen Pharma Ltd. has a 12 month low of $8.69 and a 12 month high of $24.13.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, May 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The firm had revenue of $18.78 million during the quarter, compared to analyst estimates of $20.73 million. On average, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.6 EPS for the current year.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 5,153 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $13.08, for a total transaction of $67,401.24. Following the completion of the sale, the insider now owns 144,284 shares of the company’s stock, valued at $1,887,234.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 11.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of research reports. Oppenheimer raised their target price on shares of UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Monday. Finally, LADENBURG THALM/SH SH boosted their price target on UroGen Pharma from $48.00 to $53.50 and gave the stock a “buy” rating in a research report on Friday, June 14th.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.